BioMed Realty and CordenPharma Colorado Expand Peptide Development Capacity with New Facility in Boulder
BioMed Realty, a leading private owner and operator of real estate dedicated to the life sciences, technology, and innovation sectors, has announced a major new partnership with CordenPharma’s Colorado division. The company revealed that CordenPharma Colorado, a prominent peptide drug substance Contract Development and Manufacturing Organization (CDMO), has signed a long-term lease for 64,000 square feet of laboratory space at Flatiron Park in Boulder.
The newly leased space is located in the building known as 5505 Central, which represents the first purpose-built speculative laboratory facility developed within the Flatiron Park campus. Positioned close to CordenPharma Colorado’s existing manufacturing site, the new building will support expanded peptide development operations and further strengthen Boulder’s growing reputation as a hub for life sciences innovation.
Flatiron Park, owned and operated by BioMed Realty, is recognized as one of the premier research and technology campuses in Boulder. The campus is designed to support a diverse community of tenants working in life sciences, quantum technologies, and advanced research fields. It features resilient infrastructure, adaptable building designs, and a carefully curated campus environment intended to foster collaboration, innovation, and long-term growth for scientific organizations.
The 15-year lease agreement between BioMed Realty and CordenPharma Colorado highlights the strategic importance of Flatiron Park as a center for scientific advancement. The deal also underscores BioMed Realty’s continued commitment to investing in the Boulder innovation ecosystem and creating specialized spaces that meet the evolving needs of life sciences companies.
Under the agreement, CordenPharma Colorado will occupy the entire 5505 Central building, making it the sole tenant. The facility has been constructed to meet the demanding requirements of modern laboratory and pharmaceutical development work. It has achieved LEED® Gold certification, reflecting its adherence to high environmental and sustainability standards.
The building includes a number of features designed specifically for advanced scientific operations. Among these are robust electrical power capacity to support energy-intensive research equipment, flexible laboratory grids that allow scientists to reconfigure workspaces as projects evolve, and advanced mechanical and utility systems to maintain strict environmental and operational conditions required in pharmaceutical development.
Additionally, the facility incorporates efficient waste management and disposal systems designed to handle laboratory byproducts safely and responsibly. These capabilities are critical for organizations engaged in complex chemical and biological processes such as peptide drug development.
One of the most strategic advantages of the new location is its proximity to CordenPharma Colorado’s existing large-scale peptide manufacturing plant. By situating process development and analytical laboratories next to manufacturing operations, the company aims to streamline the transition from research and development to full-scale production.
This integrated setup will enable scientists and engineers to collaborate more effectively across development stages, helping accelerate timelines for peptide Active Pharmaceutical Ingredient (API) production. From early-stage process design and analytical testing to commercial manufacturing, the facility is expected to support a seamless development pipeline for pharmaceutical clients.
The expanded development capacity in Boulder will not only serve regional operations but will also become part of CordenPharma’s broader international infrastructure. The company operates a global network of development and manufacturing facilities across Europe and the United States, and the new Boulder labs will integrate into this system to support worldwide demand for complex peptide therapeutics.
According to company leaders, the investment reflects growing demand for specialized peptide drug development services. Peptides have become an increasingly important class of therapeutic molecules, used in treatments for conditions ranging from metabolic disorders to cancer and rare diseases.
Jon Bergschneider, President of West Coast Markets at BioMed Realty, said the new facility demonstrates the company’s commitment to building specialized environments tailored for cutting-edge scientific work.
He noted that the 5505 Central building represents the first purpose-built laboratory structure within Flatiron Park designed to offer the flexibility and high performance that advanced research organizations require. Bergschneider also highlighted the broader campus ecosystem, which includes collaborative spaces, curated amenities, and BioMed Realty’s Discover Here programming—an initiative focused on fostering community and innovation among tenants.
According to Bergschneider, the combination of state-of-the-art infrastructure and a connected campus experience enables companies at Flatiron Park to focus on scientific discovery while maintaining the flexibility needed for future growth.
Michael Landau, Managing Director of CordenPharma Colorado, emphasized that the new laboratory space will play a key role in the company’s long-term growth strategy. He explained that the expansion will allow CordenPharma to respond more effectively to increasing customer demand for complex peptide outsourcing services.
Landau also noted that the project will contribute to job creation in the region and help attract highly skilled research professionals to Boulder. With the support of CordenPharma’s global network and experienced team, the new laboratories are expected to further strengthen the local life sciences sector.
He added that development laboratories are a critical foundation for CDMO operations, enabling the company to support pharmaceutical partners throughout the drug development process and ultimately help deliver effective therapies to patients.
Jennifer Chavez, Senior Director of Leasing at BioMed Realty, said the addition of CordenPharma Colorado to the Flatiron Park community reinforces the campus’s role in Boulder’s innovation landscape.
Chavez highlighted that BioMed Realty’s mission is to provide the reliable infrastructure and adaptable research environments that leading scientific companies require. By offering high-quality facilities designed specifically for research and manufacturing activities, the company helps enable organizations like CordenPharma to pursue breakthrough discoveries and commercialize new therapies.
Source link :https://www.businesswire.com/
